Next Article in Journal
Expansion of T Cells with Interleukin-21 for Adoptive Immunotherapy of Murine Mammary Carcinoma
Next Article in Special Issue
Perindopril Induces TSP-1 Expression in Hypertensive Patients with Endothelial Dysfunction in Chronic Treatment
Previous Article in Journal
Uridine Triphosphate Thio Analogues Inhibit Platelet P2Y12 Receptor and Aggregation
Previous Article in Special Issue
Cell-Free RNA Content in Peripheral Blood as Potential Biomarkers for Detecting Circulating Tumor Cells in Non-Small Cell Lung Carcinoma
Article Menu
Issue 2 (February) cover image

Export Article

Open AccessReview
Int. J. Mol. Sci. 2017, 18(2), 264; doi:10.3390/ijms18020264

Circulating Cell Free Tumor DNA Detection as a Routine Tool forLung Cancer Patient Management

1
CHU Montpellier, Arnaud de Villeneuve Hospital, Department of Pathology, 34295 Montpellier, France
2
IRCM, Institut de Recherche en Cancérologie de Montpellier, 34298 Montpellier, France
3
INSERM, U1194, 34298 Montpellier, France
4
ICM, Institut Régional du Cancer de Montpellier, 34298 Montpellier, France
5
Université de Montpellier, 34000 Montpellier, France
6
CHU Montpellier, Arnaud de Villeneuve Hospital, Department of Microbiology, 34295 Montpellier, France
*
Author to whom correspondence should be addressed.
Academic Editor: William Chi-shing Cho
Received: 29 November 2016 / Revised: 10 January 2017 / Accepted: 18 January 2017 / Published: 29 January 2017
(This article belongs to the Special Issue Liquid Biopsy for Clinical Application)
View Full-Text   |   Download PDF [1722 KB, uploaded 6 February 2017]   |  

Abstract

Circulating tumoral DNA (ctDNA), commonly named “liquid biopsy”, has emerged as a new promising noninvasive tool to detect biomarker in several cancers including lung cancer. Applications involving molecular analysis of ctDNA in lung cancer have increased and encompass diagnosis, response to treatment, acquired resistance and prognosis prediction, while bypassing the problem of tumor heterogeneity. ctDNA may then help perform dynamic genetic surveillance in the era of precision medicine through indirect tumoral genomic information determination. The aims of this review were to examine the recent technical developments that allowed the detection of genetic alterations of ctDNA in lung cancer. Furthermore, we explored clinical applications in patients with lung cancer including treatment efficiency monitoring, acquired therapy resistance mechanisms and prognosis value. View Full-Text
Keywords: circulating DNA; molecular diagnosis; targeted therapies; routine practice; lung cancer circulating DNA; molecular diagnosis; targeted therapies; routine practice; lung cancer
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Vendrell, J.A.; Mau-Them, F.T.; Béganton, B.; Godreuil, S.; Coopman, P.; Solassol, J. Circulating Cell Free Tumor DNA Detection as a Routine Tool forLung Cancer Patient Management. Int. J. Mol. Sci. 2017, 18, 264.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top